Halozyme Therapeutics HALO Operating margin
Operating margin at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's operating margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's operating margin?
- Halozyme Therapeutics (HALO) reported operating margin of 59.3% in Q3 2025.
- How has Halozyme Therapeutics's operating margin changed year-over-year?
- Halozyme Therapeutics's operating margin increased by 17.8% year-over-year, from 50.4% to 59.3%.
- What is the long-term trend for Halozyme Therapeutics's operating margin?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's operating margin has grown at a 0.2% compound annual growth rate (CAGR), from 53.9% to 54.3%.
- What does operating margin mean?
- The profit left from core operations for every dollar of sales, before interest and taxes.
- How do you interpret operating margin?
- Expanding operating margin shows operating leverage — revenue growing faster than the cost base. Compression points to rising overhead, pricing pressure, or investment ahead of revenue.
- How does operating margin compare across companies?
- Strong cross-company signal within a sector. Capital-light businesses sustain higher operating margins than capital-intensive ones.